These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35090987)

  • 21. Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
    Taniguchi T; Ohtani T; Mizote I; Kanzaki M; Ichibori Y; Minamiguchi H; Asano Y; Sakata Y; Komuro I
    J Cardiol; 2013 Jun; 61(6):417-22. PubMed ID: 23548374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of deep-learning models for real-time anaerobic threshold and peak VO2 prediction during cardiopulmonary exercise testing.
    Watanabe T; Tohyama T; Ikeda M; Fujino T; Hashimoto T; Matsushima S; Kishimoto J; Todaka K; Kinugawa S; Tsutsui H; Ide T
    Eur J Prev Cardiol; 2024 Mar; 31(4):448-457. PubMed ID: 38078901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol.
    Guazzi M; Agostoni P; Matturri M; Pontone G; Guazzi MD
    Am Heart J; 1999 Sep; 138(3 Pt 1):460-7. PubMed ID: 10467196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lvad pump speed increase is associated with increased peak exercise cardiac output and vo
    Vignati C; Apostolo A; Cattadori G; Farina S; Del Torto A; Scuri S; Gerosa G; Bottio T; Tarzia V; Bejko J; Sisillo E; Nicoli F; Sciomer S; Alamanni F; Paolillo S; Agostoni P
    Int J Cardiol; 2017 Mar; 230():28-32. PubMed ID: 28038810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Congestive heart failure in Spain: cost-effectiveness and cost-benefit analyses of treatment with beta-blockers].
    Díez Manglano J
    Rev Clin Esp; 2005 Apr; 205(4):149-56. PubMed ID: 15860185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.
    Fröhlich H; Torres L; Täger T; Schellberg D; Corletto A; Kazmi S; Goode K; Grundtvig M; Hole T; Katus HA; Cleland JGF; Atar D; Clark AL; Agewall S; Frankenstein L
    Clin Res Cardiol; 2017 Sep; 106(9):711-721. PubMed ID: 28434020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure.
    Aygul N; Ozdemir K; Duzenli MA; Aygul MU
    Cardiology; 2009; 112(3):168-73. PubMed ID: 18654081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study.
    Sessa M; Mascolo A; Rasmussen DB; Kragholm K; Jensen MT; Sportiello L; Rafaniello C; Tari GM; Pagliaro C; Andersen M; Rossi F; Capuano A
    Sci Rep; 2019 Aug; 9(1):11465. PubMed ID: 31391573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol.
    Stoschitzky K; Stoschitzky G; Brussee H; Bonelli C; Dobnig H
    Cardiology; 2006; 106(4):199-206. PubMed ID: 16679760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
    Tang CH; Wang CC; Chen TH; Hong CY; Sue YM
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26738790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carvedilol Does Not Improve Exercise Performance in Fontan Patients: Results of a Crossover Trial.
    Butts R; Atz AM; BaezHernandez N; Sutcliffe D; Reisch J; Mahony L
    Pediatr Cardiol; 2021 Apr; 42(4):934-941. PubMed ID: 33585998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of carvedilol on oxygen uptake and heart rate kinetics in patients with chronic heart failure at simulated altitude.
    Karsten M; Contini M; Cefalù C; Cattadori G; Palermo P; Apostolo A; Bussotti M; Magrì D; Salvioni E; Farina S; Sciomer S; Catai AM; Agostoni P
    Eur J Prev Cardiol; 2012 Jun; 19(3):444-51. PubMed ID: 21450573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
    Kubota Y; Asai K; Furuse E; Nakamura S; Murai K; Tsukada YT; Shimizu W
    Int J Chron Obstruct Pulmon Dis; 2015; 10():515-23. PubMed ID: 25784798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different impact of carvedilol and transdermal scopolamine on cardiovascular performance of mild-moderate chronic heart failure patients: evidence of useful effects of scopolamine on tolerance to work load.
    De Vecchis R; Pucciarelli G; Setaro A; Nocerino L
    Minerva Cardioangiol; 2000 Nov; 48(11):393-410. PubMed ID: 11214431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of β-blocker cessation on chronotropic incompetence and exercise tolerance in patients with advanced heart failure.
    Hirsh BJ; Mignatti A; Garan AR; Uriel N; Colombo P; Sims DB; Jorde UP
    Circ Heart Fail; 2012 Sep; 5(5):560-5. PubMed ID: 22855557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure.
    Podbregar M; Voga G
    J Card Fail; 2002 Dec; 8(6):369-78. PubMed ID: 12528088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for beta-blocker selection.
    Chin BS; Gibbs CR; Blann AD; Lip GY
    Clin Sci (Lond); 2003 Oct; 105(4):507-12. PubMed ID: 12841846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cardiopulmonary exercise testing (CPET)to evaluate the efficacy after intensive control of personalized precise exercise training for cardiovascular and cerebrovascular chronic diseases].
    Song Y; Sun XG; Xie YH; Tai WQ; Wang JN; Zhang Y; Zhang YF; Shi C; He LL; Hao L; Liu F; Feng J; Zhang ZY; Liu YL; Yu H
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2021 Jan; 37(1):79-88. PubMed ID: 34672467
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure.
    Kovacić D; Marinsek M; Gobec L; Lainscak M; Podbregar M
    Clin Res Cardiol; 2008 Jan; 97(1):24-31. PubMed ID: 17694376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limited predictive value of cardiopulmonary exercise indices in patients with moderate chronic heart failure treated with carvedilol.
    Corrà U; Mezzani A; Bosimini E; Scapellato F; Temporelli PL; Eleuteri E; Giannuzzi P
    Am Heart J; 2004 Mar; 147(3):553-60. PubMed ID: 14999209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.